

PROVINCIAL FUNDING SUMMARY

Everolimus (Afinitor) for Pancreatic Neuroendocrine Tumours

pERC Recommendation: Recommend with condition on the cost-effectiveness being improved to an acceptable level

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: September 17, 2012

This information is current as of October 27, 2014. The use of this document is directed by [pCODR's Terms of Use](#).

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	Jun 1, 2011	Well to moderately differentiated, unresectable or metastatic pancreatic neuroendocrine tumours (PNET); ECOG performance status 0 - 2; adequate hematologic, hepatic and renal function; and Compassionate Access Program (CAP) approval granted by BCCA. (Note: Approvals will only be given for one of sunitinib or everolimus - not both, unless due to intolerance within the first month of therapy.)
AB	Funded	Mar 25, 2013	Well or moderately-differentiated neuroendocrine tumours of pancreatic origin (pNETs) in patients with unresectable, locally advanced or metastatic disease who have not previously been treated with sunitinib (unless intolerant)
SK	Funded	Feb 1, 2013	Treatment of patients with progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (pNET) with good performance status (ECOG 0-2) Note: Patients whose disease progresses on Everolimus are not eligible for SCA funded treatment with Sunitinib for pNET
MB	Funded	Jul 17, 2014	For the treatment of patients with progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (pNET) with good performance status (ECOG0-2), until disease progression.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
ON	Funded	Nov 8, 2013	<p>Initial approval: For patients who have progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (“pNET”) with good performance status (ECOG 0-2), until disease progression.</p> <p>Exclusion criteria: the patient’s disease progressed while taking sunitinib to treat pNET</p> <p>Renewal criteria: The Patient’s physician has confirmed that the Patient has benefited or continues to benefit from therapy with the Afinitor Product, as evidenced by no disease progression, and is expected to continue to do so.</p> <p>Approval duration: 1 year</p>
NS	Funded	Oct 1, 2014	<p>For the treatment of patients with progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (pNET) with good performance status (ECOG 0-2), until disease progression</p>
NB	Funded	Dec 19, 2013	<p>For the treatment of patients with progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumours (pNET) with good performance status (ECOG 0-2), until disease progression.</p> <p>Dose: maximum 10mg daily.</p>
NL	Funded	Mar 6, 2014	<p>For the treatment of patients with progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (pNET) with good performance status (ECOG 0-2), until disease progression.</p> <p>Note: Patients whose disease progresses on sunitinib are not eligible for funded treatment with everolimus for pNET</p> <p>Approval Period: 12 months Recommended Dose: 10mg daily until disease progression or development of unacceptable toxicity requiring discontinuation of everolimus</p> <p>Renewals will be considered for patients who do not have evidence of disease progression AND who have not developed unacceptable toxicities that require discontinuation of everolimus.</p>
PEI	Under provincial consideration*		

**Under provincial consideration* means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pricing Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.